期刊名称：ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 ASSAY and Drug Development Technologies is the only authoritative, peer-reviewed journal that provides early-stage screening techniques and tools that enables you to optimize and identify novel leads and targets for new drug development.
Each issue includes:
- Assay design and target development
- High throughput technologies and chemistry
- Lab automation and sample management
- Data analysis and information management
- Bioinformatics, data mining, and virtual screening
- Biosensors and detection technologies
- Miniaturization, microfluidics, and nanotechnology
- Novel screening methods with high information content
- Metabolically engineered cells and organisms
- Imaging technologies for live cells, tissues, and small animals
Instructions to Authors
ASSAY and Drug Development Technologies focuses on early-stage screening techniques and tools that optimize the identification of novel leads and targets for new drug development, running the spectrum from nanotechnology through cellular imaging. Case studies are presented, and technology applications are extensive. Articles published in ASSAY emphasize methodologies and technologies to accelerate drug discovery.
Articles include state-of-the-art research, methods, materials, and protocols in assay design and target development; High throughput screening; High throughput chemistry; Lab automation; Data analysis and information management; Microplate standards; Screen design and advanced technology; Protein structure and function; Compound library generation; Bioinformatics and data mining; Validation strategies; Biosensors; Detection technologies; Miniaturization and nanotechnology; Protein-protein interaction as novel drug targets; Novel screening methods with high information content; Metabolically engineered cells and organisms; Imaging technologies for live cells, tissues, and small animals; and Virtual screening.
Manuscripts submitted to this Journal must not be under consideration elsewhere.
All manuscripts must be submitted online using the following URL: http://mc.manuscriptcentral.com/assay
English Grammar and Style Refinement
The Editors’ goal is for ASSAY and Drug Development Technologies to provide a global forum that promotes discourse among drug discovery researchers worldwide. Thus submission of articles by authors from non-English speaking countries is strongly encouraged. Authors whose native language is not English are advised to use an editing service to refine the manuscript before submission to ASSAY. Peer reviewers will then be able to evaluate the scientific content and organization of a paper without becoming distracted by grammatical details. Our aim is to avoid the obscuring of excellent science by a difficult-to-read manuscript.
Expert editors at Mary Ann Liebert, Inc. are available to refine your manuscript for word usage, grammar, sentence construction, and formatting prior to submission for peer review. Please note that use of this editing service does not guarantee acceptance by ASSAY and Drug Development Technologies. After editing, the paper will go through the usual full peer-review process. Even if the paper is not accepted by the Journal, it will have been substantially improved and may then be submitted for publication in another journal. For further information and costs, please e-mail Georgia Prince at the publisher’s office: EditingServices@liebertpub.com Please be sure to include the name of the Journal and whether or not the paper has been officially submitted to the Journal. Alternatively, authors may select from one of the numerous scientific editing services that may be found through a web-based search.
The Copyright Agreement form (available from web site at http://www.liebertpub.com/Mcontent/Files/transfer_of_copyright.pdf.) should be submitted once your paper has been accepted for publication. Manuscripts cannot be published without this form. The corresponding author is responsible for obtaining signatures of coauthors. Authors not permitted to release copyright must still return the form signed under the statement of the reason for not releasing the copyright. Upon acceptance of your paper, please fax the Copyright Agreement form to 914-740-2108.
PREPARATION OF MANUSCRIPTS
IMPORTANT:
Please upload individual files of all manuscript material – do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
The Journal will publish color photographs, but the author must subsidize the cost of the color printing. For further details, contact the Publisher.
Submissions of manuscripts must be double-spaced with margins of 1 inch on each side, and ample space on top and bottom.
PLEASE FOLLOW THIS
SEQUENCE OF SECTIONS:
- Number each page of text consecutively. Number all figures and tables.
- Title page must contain: 1) the complete title of the paper; 2) the full names (including first names), full mailing addresses, full contact information (telephone, fax, and E-mail address), and affiliations of each author; 3) a brief running title; 4) the corresponding author’s complete contact information including full mailing and E-mail addresses.
- Title: Please do not use “Novel” or “New” in the article title.
- Abstract: 250 words or less, without the use of subheadings. References are not permitted in the abstract.
- Introduction: Summarize the background of the technology and its significance and novelty. Results should NOT be included in the introduction.
- Materials and Methods: ASSAY and Drug Development Technologies is method oriented. Sources
of specific materials, including reagents, software, and instrumentation, should be specified, marked
with ™ or ® if they are trademarked or registered. These marks need only be cited at the product’s
first mention in the abstract, and then once again in text. All acronyms and their definitions should be
spelled out in a separate list on a separate page immediately after the title page. Use only acronyms
in text. When using specific brand names of drugs or devices, please include the manufacturer’s
name and location (including city and state) in parentheses.
-
Results.
-
Discussion: The results and discussion sections of short articles may be combined for more effective
presentation.
-
Acknowledgments.
AUTHOR DISCLOSURE STATEMENT
All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.
TABLES AND ILLUSTRATIONS
Use Arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences. Provide titles for all tables. Define all acronyms in table footnotes. All other types of table footnotes should be designated using superscript letters, not symbols.
All illustrations should be numbered and labeled with the first author’s name. A legend should be supplied for each illustration, and all legends numbered consecutively and provided (double spaced). All symbol definitions should be in figure legend, not as a key within the figure. If possible please use Arial font for figure text.
A legend should be supplied for each figure, and all legends numbered consecutively and provided (double spaced) on a separate page at the end of the main text file. Figures should be numbered in the order cited in the text. Images should not show the name of a manufacturer or reveal patients’ name(s).
Please keep in mind that the figures will be reduced, so please do not submit large figures/graphs that contain small type, as the text within the figure will not be readable after reduction.
Please follow these instructions carefully when preparing figure files for uploading:
• Do NOT include any illustrations as part of your text file.
• Do not prepare any figures in Word as they are not workable and will be rejected for reproduction.
• Line illustrations must be submitted at 900 DPI.
• Halftones and color photos should be submitted at a minimum of 300 DPI. (NB: 600 DPI images are more desirable for reproduction.)
• Power Point files cannot be uploaded on to Manuscript Central.
• Save art as either TIFF or EPS files. Do not submit JPEG files. (JPEG files are for screen representation-quality only and will print very poorly during the printing process.) To ensure proper print quality, please submit only TIFF or EPS files.
• Color art must be saved as CYMK, not RGB. NB: If RGB files are submitted, the files will be converted to CYMK and some color variation will occur.
• Label figures and tables inside the files in addition to naming the file with the figure or table number. (ie: When figures or table files are opened, the figure or table number should appear inside the file.)
Chemical Structures. Structures should be produced with the use of a drawing program such as ChemDraw. Authors using the current versions of ChemDraw will find the necessary parameters incorporated into this program (“ACS Document 1996”).
REFERENCES
All references must be cited in the text using a superscript Arabic number. Arrange the reference list in numeric order as cited in the text. Abbreviate journal names according to Serial Sources for the BIOSIS Data Base (BioSciences Information Service, 1992). References should be presented in the following style: Journal citation: Ferrer M, Hamilton A, Inglese J: A PDZ domain-based detection system for enzyme assays. Analyt Biochem 2001;301:207–216. Book citation: Kahn M: High Throughput Screening for Novel Anti-Inflammatories. Birkhauser, Basel, Switzerland, 2000. Chapter in edited book: Banks M: Automation and Technology for HTS in Drug Development. In: Approaches to High Throughput Toxicity Screening. Atterwill CK, Purcell W, Goldfarb P, (eds.), pp. 9–30. Taylor & Francis, London, UK, 1999. Web sites: Name of web page. Web address. (Last accessed on [date]).
When dates from an unpublished source are given, supply the researcher’s name. If the work is in press, give the journal in which it is to be published.
PERMISSIONS
• The author must obtain written permission from the publisher of the journal or book concerned for the reproduction of figures, tables, etc. from copyrighted materials.
• The publication from which the figure or table is reprinted must be listed as a complete reference in the reference list.
• An appropriate credit line should be included in the figure legend or table footnote.
COPYRIGHT
Unless rejected for publication, all submissions become the property of Mary Ann Liebert, Inc.
page proofs
Page proofs are sent to the corresponding author via email, so please be sure to have any email filters accept emails from the liebertpub.com domain. Please ensure that current email addresses are given. Because ASSAY and Drug Development Technologies is a rapid-publication journal, we request that page proofs containing corrections be returned to the Publisher within 24 hours of receipt. If the corresponding author expects to be unavailable at the time proofs are anticipated, please notify the Publisher and provide an alternate corresponding author and email address.
REPRINTS
Reprints may be ordered by following the special instructions that will accompany page proofs. Reprints can be provided with the cover of the Journal. Reprints ordered after the issue is printed will be charged at a significantly higher rate.
Editorial Board
Editor-in-Chief
Jim Inglese, Ph.D.
Bethesda, MD
Assistant Editor
Wei Zheng, Ph.D.
Bethesda, MD
Literature Editors
Doug Auld, Ph.D.
Bethesda, MD
Anton Simeonov, Ph.D.
Bethesda, MD
Editorial Board
Christopher P. Austin, M.D.
Bethesda, MD
Stephen J. Benkovic, Ph.D.
Pennsylvania State University
University Park, PA
Leo S. Bleicher
Cepheus Information Systems
San Diego, CA
Robert W. Bryant, Ph.D.
Redpoint Bio Corporation
Cranbury, NJ
Jonathan J. Burbaum, Ph.D.
Gnosys Consulting
Del Mar, CA
Susan Catalano, Ph.D.
Drug Discovery Imaging
Hayward, CA
Daniel Chelsky, Ph.D.
Caprion Pharmaceuticals
Montreal, Quebec
Canada
Richard M. Eglen, Ph.D.
PerkinElmer Life and Analytical Sciences
Wellesley, MA
Scott Eliasof, Ph.D.
Tempo Pharmaceuticals, Inc.
Cambridge, MA
Thomas L. Fare, Ph.D.
Rosetta Inpharmatics LLC
Seattle, WA
Dan Fitzpatrick, Ph.D.
Amgen, Inc.
Thousand Oaks, CA
J. Fraser Glickman, MPH, Ph.D.
Novartis Institutes for Biomedical Research
Basel, Switzerland
Ilkka Hemmil? Ph.D.
PerkinElmer Life Sciences
Turku, Finland
Mats Inganäs, Ph.D.
Gyros AB
Uppsala, Sweden
Robert J. Lefkowitz, M.D.
HHMI/Duke University Medical Center
Durham, NC
Yuan-Chi Lin, M.D., M.P.H.
Harvard Medical School
Boston, MA
Chaoyong Ma, Ph.D., MBA
Merck Research Laboratories
Boston, MA
Ralph R. Martel, Ph.D.
High Throughput Genomics, Inc.
Tucson, AZ
Kevin R. Oldenburg, Ph.D.
MatriCal
Spokane, WA
Young-Whan Park, Ph.D.
Merck & Co., Inc.
Rahway, NJ
Brian A. Pollok, Ph.D.
Invitrogen Life Technologies
Madison, WI
Peter Ramm, Ph.D.
Invicta Research, Inc.
St. Catherines, Ontario
Canada
J. Michael Ramsey, Ph.D.
University of North Carolina
Chapel Hill, NC
John R. Raymond, M.D.
Medical University of South Carolina
Charleston, SC
F. Raymond Salemme, Ph.D.
Redpoint Bio Corporation
Cranbury, NJ
Caroline E. Shamu, Ph.D.
Harvard Medical School
Boston, MA
R. Eryl Sharp, Ph.D.
Pfizer, Inc.
Groton, CT
Kazunari Taira, Ph.D.
The University of Tokyo
Tokyo, Japan
Jeffrey H. Toney, Ph.D.
Montclair State University
Upper Montclair, NJ
C. David Weaver, Ph.D.
Vanderbilt Medical School
Nashville, TN
David A. Zacharias, Ph.D.
University of Florida
St. Augustine, FL
Guido J.R. Zaman, Ph.D.
N.V. Organon
Oss, The Netherlands
Managing Editor
Susan K. Jensen
Mary Ann Liebert, Inc., publishers
140 Huguenot Street
3rd Floor
New Rochelle, NY 10801
Tel: 914-740-2100
Fax: 914-740-2108
sjensen@liebertpub.com
|
